Salute e Benessere
Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an enhanced liquid biopsy platform for sensitive detection of low-abundance RNA
The method identified novel isoforms of key cancer genes HER2 and TROP2 in patient blood samples, allowing more effective ADC development and more accurate patient stratification.
Dr. Richard Kuo , Wobble Genomics CEO and Founder, said: "Our new platforms mark a major breakthrough in liquid biopsy technology, delivering highly sensitive and accurate detection of cancer transcripts directly from whole blood. The promising data shared today represents an important step towards establishing an effective diagnostic tool, transforming how cancers are treated."
The details of the poster presentation are as follows:
Analytical Performance of a Novel Long-Read RNA Sequencing Assay for Low-Abundance Cancer Transcript Detection from Whole Blood
Available digitally (e-poster on conference searchable screens)
17 -21 October
Yuanyuan Cheng, Oliver Eve ,
Katrina Morris , Alice Séguret, Mark Barnett ,
Ivayla Ivanova , Ahmad Zyoud ,
Gabriel Benitez , Jacob Bradley ,
John Davey , Amy Robinson ,
Arran Turnbull , J Michael Dixon,
Rick Hockett , Han-Yu Chuang ,
Richard I. Kuo
Wobble Genomics is an innovative healthcare and biotechnology company at the forefront of highly sensitive long-read cfRNA liquid biopsy diagnostics, whose mission is to understand and better treat cancer, and other diseases over time, in a new way. The company was founded by Dr. Richard Kuo at The Roslin Institute, at The University of Edinburgh . The company is backed by a world-leading panel of advisors in genomics, diagnostics and oncology. Wobble Genomics is currently conducting clinical studies in partnership with the National Health Service (NHS) in the UK.
For more information about Wobble Genomics, please visit wobblegenomics.com. You can follow Wobble Genomics on LinkedIn.
Emma Kosian , Hawthorn Advisors
Email: e.kosian@hawthornadvisors.com
Phone: +44 7444 840575
View original content:https://www.prnewswire.co.uk/news-releases/wobble-genomics-presents-latest-data-at-esmo-establishing-the-robustness-of-an-enhanced-liquid-biopsy-platform-for-sensitive-detection-of-low-abundance-rna-302587692.html